Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults With Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Physician diagnosis of atopic dermatitis for greater than (\>) 1 year~* Atopic dermatitis involvement of greater than or equal to (\>=) 10 percent (%) body surface area~* EASI score of \>= 12~* SCORAD of \>= 25~* IGA score of \>= 3~* Effective birth control in line with protocol details~Exclusion Criteria:~* History of anaphylaxis following any biologic therapy~* Hepatitis B, C or human immunodeficiency virus~* Pregnant or breastfeeding~* History of cancer~* Previous receipt of tralokinumab

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched to Tralokinumab will be administered subcutaneously to participants once every 2 Weeks (Q2W) for 12 weeks.
- Tralokinumab Dose 1 (Type: EXPERIMENTAL): Tralokinumab Dose 1 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
- Tralokinumab Dose 2 (Type: EXPERIMENTAL): Tralokinumab Dose 2 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.
- Tralokinumab Dose 3 (Type: EXPERIMENTAL): Tralokinumab Dose 3 will be administered subcutaneously once every 2 Weeks (Q2W) for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).